2D 3D
	ID	DDInter2029
	Drug Type	small molecule
	Molecular Formula	C27H52N3O7P
	Molecular Weight	561.701
	CAS Number	444805-28-1
	Description	Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy.[A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. Cidofovir itself has broad antiviral activity against several DNA viruses,[A235725] resulting in brincidofovir being investigated for the prevention and treatment of cytomegalovirus (CMV), BK Virus (BKV), adenoviruses (AdV), and Epstein-Barr virus (EBV), amongst others. Brincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.[L34470] As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola. The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible.
	ATC Classification	J05AB17
IUPAC Name	({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid
InChI	WXJFKKQWPMNTIM-VWLOTQADSA-N
Canonical SMILES	CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O
Useful Links	DrugBank PubChem Substance ChemSpider Wikipedia ChEMBL ZINC